Vise Technologies Inc. Makes New $608,000 Investment in Medpace Holdings, Inc. $MEDP

Posted by Brian Himes on Aug 25th, 2026

Vise Technologies Inc. purchased a new position in Medpace Holdings, Inc. (NASDAQ:MEDP – Free Report) in the 2nd quarter, Holdings Channel reports. The institutional investor purchased 1,149 shares of the company’s stock, valued at approximately $608,000.

A number of other hedge funds also recently modified their holdings of the business. Johnson Financial Group Inc. bought a new position in shares of Medpace during the 2nd quarter valued at about $27,000. Geneos Wealth Management Inc. increased its stake in Medpace by 64.9% during the 1st quarter. Geneos Wealth Management Inc. now owns 94 shares of the company’s stock worth $29,000 after purchasing an additional 37 shares in the last quarter. Elyxium Wealth LLC bought a new stake in Medpace during the 4th quarter worth approximately $30,000. Allied Private Wealth LLC acquired a new stake in Medpace during the 2nd quarter worth approximately $31,000. Finally, Basecamp Wealth Advisors LLC raised its holdings in Medpace by 187.5% during the 1st quarter. Basecamp Wealth Advisors LLC now owns 69 shares of the company’s stock worth $33,000 after buying an additional 45 shares during the period. Institutional investors and hedge funds own 77.98% of the company’s stock.

Medpace Stock Performance

MEDP opened at $620.03 on Tuesday. Medpace Holdings, Inc. has a 52-week low of $373.00 and a 52-week high of $677.90. The firm has a market capitalization of $17.31 billion, a PE ratio of 36.34, a PEG ratio of 2.77 and a beta of 1.15. The business’s 50-day simple moving average is $553.21 and its 200 day simple moving average is $492.40.

Medpace (NASDAQ:MEDP – Get Free Report) last posted its quarterly earnings results on Wednesday, July 22nd. The company reported $4.25 earnings per share for the quarter, beating analysts’ consensus estimates of $3.98 by $0.27. The firm had revenue of $707.33 million during the quarter, compared to the consensus estimate of $689.51 million. Medpace had a return on equity of 110.15% and a net margin of 17.67%.The business’s revenue was up 17.2% compared to the same quarter last year. During the same period last year, the company earned $3.10 earnings per share. Medpace has set its FY 2026 guidance at 17.250-17.950 EPS. On average, research analysts forecast that Medpace Holdings, Inc. will post 17.54 earnings per share for the current year.

Wall Street Analyst Weigh In

Several research analysts have recently weighed in on MEDP shares. Mizuho upped their price target on shares of Medpace from $586.00 to $665.00 and gave the company an “outperform” rating in a report on Friday, July 24th. Royal Bank Of Canada boosted their price objective on shares of Medpace from $484.00 to $692.00 and gave the company an “outperform” rating in a research report on Friday, July 24th. Truist Financial increased their target price on Medpace from $462.00 to $609.00 and gave the stock a “hold” rating in a report on Friday, July 24th. Deutsche Bank Aktiengesellschaft restated a “hold” rating and issued a $535.00 price target on shares of Medpace in a report on Thursday, July 23rd. Finally, Robert W. Baird upped their price objective on Medpace from $547.00 to $624.00 and gave the stock a “neutral” rating in a research report on Friday, July 24th. Three investment analysts have rated the stock with a Buy rating and ten have given a Hold rating to the company. According to data from MarketBeat.com, the company currently has a consensus rating of “Hold” and an average target price of $584.18.

Read Our Latest Report on Medpace

Insider Buying and Selling

In related news, CFO Kevin M. Brady sold 3,400 shares of the business’s stock in a transaction on Thursday, August 20th. The shares were sold at an average price of $625.24, for a total transaction of $2,125,816.00. Following the transaction, the chief financial officer directly owned 12,830 shares in the company, valued at approximately $8,021,829.20. The trade was a 20.95% decrease in their ownership of the stock. The sale was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Also, Director Cornelius P. Mccarthy III sold 1,140 shares of the company’s stock in a transaction on Tuesday, August 11th. The stock was sold at an average price of $605.37, for a total transaction of $690,121.80. Following the sale, the director directly owned 12,275 shares in the company, valued at $7,430,916.75. This trade represents a 8.50% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. Insiders have sold a total of 125,661 shares of company stock worth $73,854,945 in the last quarter. 20.50% of the stock is owned by company insiders.

About Medpace

(Free Report)

Medpace Holdings, Inc (NASDAQ: MEDP) is a global contract research organization (CRO) that provides comprehensive clinical development services to biotechnology, pharmaceutical and medical device companies. The company supports clinical trials across all phases (I–IV), offering end-to-end solutions designed to streamline the development process and accelerate the delivery of new therapies to market.

Medpace’s core service offerings include clinical pharmacology, regulatory affairs consulting, project management, central laboratory services, imaging, data management and biostatistics, pharmacovigilance and medical writing.